Literature DB >> 2314423

Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome.

P Bertozzi1, B Astedt, L Zenzius, K Lynch, F LeMaire, W Zapol, H A Chapman.   

Abstract

Abundant deposition of bronchoalveolar fibrin and fibronectin occurs during the exudative phase of the adult respiratory distress syndrome (ARDS), promoting hyaline-membrane formation and subsequent alveolar fibrosis. To explore the mechanisms that account for the persistence of bronchoalveolar fibrin and fibronectin, we compared the activity of urokinase, which is necessary for plasminogen activation and fibrin degradation, in cell-free bronchoalveolar-lavage fluid from 8 patients with ARDS, 9 patients with acute pulmonary diseases other than ARDS, and 10 normal subjects. The mean level of urokinase activity in the lavage fluid from the patients with ARDS was 0.003 IU per milliliter of fluid (range, 0 to 0.008), which was significantly lower (P = 0.001) than the level in the fluid from either the patients with pulmonary diseases other than ARDS (0.118 IU per milliliter [range, 0.032 to 0.295]) or the normal subjects (0.129 IU per milliliter [range, 0.045 to 0.198]). The lavage fluid from all the patients with ARDS also had antiplasmin activity, which would promote the persistence of fibrin. A true decrease in urokinase activity was confirmed by the failure of the lavage fluid from the patients with ARDS to convert [125I]plasminogen to plasmin. Despite the low urokinase activity, immunochemical assays revealed normal levels of urokinase antigen in the fluid from the patients with ARDS, suggesting the presence of urokinase inhibitors. Inhibitors were demonstrated directly by a fibrin gel-underlay assay that detects complexes of urokinase with inhibitors. Plasminogen-activator inhibitor type 1 was the principal inhibitor identified. We conclude that increased antifibrinolytic activity due to both urokinase inhibitors and antiplasmins in the bronchoalveolar compartment of patients with ARDS contributes to the formation and persistence of hyaline membranes, a key component of alveolar histopathology in ARDS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2314423     DOI: 10.1056/NEJM199003293221304

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  66 in total

1.  Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system.

Authors:  Yashodhar P Bhandary; Shwetha K Shetty; Amarnath S Marudamuthu; Margaret R Gyetko; Steven Idell; Mehrnaz Gharaee-Kermani; Rashmi S Shetty; Barry C Starcher; Sreerama Shetty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-02       Impact factor: 5.464

2.  The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.

Authors:  Kristy A Bauman; Scott H Wettlaufer; Katsuhide Okunishi; Kevin M Vannella; Joshua S Stoolman; Steven K Huang; Anthony J Courey; Eric S White; Cory M Hogaboam; Richard H Simon; Galen B Toews; Thomas H Sisson; Bethany B Moore; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

3.  Interstitial collagenase (matrix metalloproteinase-1) expresses serpinase activity.

Authors:  P E Desrochers; J J Jeffrey; S J Weiss
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

4.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

Authors:  D A Waltz; L R Natkin; R M Fujita; Y Wei; H A Chapman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

5.  Induction of the plasminogen activator system by mechanical stimulation of human bronchial epithelial cells.

Authors:  Eric K Chu; Jason Cheng; John S Foley; Brigham H Mecham; Caroline A Owen; Kathleen J Haley; Thomas J Mariani; Isaac S Kohane; Daniel J Tschumperlin; Jeffrey M Drazen
Journal:  Am J Respir Cell Mol Biol       Date:  2006-06-22       Impact factor: 6.914

6.  Increased transforming growth factor beta 1 expression mediates ozone-induced airway fibrosis in mice.

Authors:  Ashwini Katre; Carol Ballinger; Hasina Akhter; Michelle Fanucchi; Dae-Kee Kim; Edward Postlethwait; Rui-Ming Liu
Journal:  Inhal Toxicol       Date:  2011-07       Impact factor: 2.724

7.  Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation.

Authors:  Peter Dahlem; Albert P Bos; Jack J Haitsma; Marcus J Schultz; Joost C M Meijers; Burkhard Lachmann
Journal:  Intensive Care Med       Date:  2005-03-08       Impact factor: 17.440

Review 8.  Prevention and therapy of the adult respiratory distress syndrome.

Authors:  B Temmesfeld-Wollbrück; D Walmrath; F Grimminger; W Seeger
Journal:  Lung       Date:  1995       Impact factor: 2.584

Review 9.  [Pathophysiology of acute lung injury in severe burn and smoke inhalation injury].

Authors:  M O Maybauer; S Rehberg; D L Traber; D N Herndon; D M Maybauer
Journal:  Anaesthesist       Date:  2009-08       Impact factor: 1.041

10.  Hyaluronan (hyaluronic acid) in lung lavage of asbestos-exposed humans and sheep.

Authors:  A M Cantin; P Larivée; M Martel; R Bégin
Journal:  Lung       Date:  1992       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.